Banque Cantonale Vaudoise’s NovoCure NVCR Stock Holding History

Banque Cantonale Vaudoise’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,500	Closed	-$104K	–	1201
2023 Q2	$104K	Hold	2,500	–	–	﹤0.01%	849
2023 Q1	$150K	Hold	2,500	–	–	0.01%	773
2022 Q4	$183K	Hold	2,500	–	–	0.01%	732
2022 Q3	$190K	Hold	2,500	–	–	0.01%	737
2022 Q2	$174K	Hold	2,500	–	–	0.01%	775
2022 Q1	$207K	Hold	2,500	–	–	0.01%	788
2021 Q4	$188K	Hold	2,500	–	–	0.01%	843
2021 Q3	$290K	Sell	2,500 -3,800	-60%	-$575K	0.01%	716
2021 Q2	$1.4M	Sell	6,300 -100	-2%	-$19.5K	0.06%	336
2021 Q1	$847K	Buy	6,400 +4,648	+265%	+$735K	0.04%	407
2020 Q4	$303K	Buy	1,752 +9	+0.5%	+$1.23K	0.02%	635
2020 Q3	$194K	Sell	1,743 -72	-4%	-$5.76K	0.01%	687
2020 Q2	$108K	Sell	1,815 -706	-28%	-$46.4K	0.01%	768
2020 Q1	$170K	Sell	2,521 -175	-6%	-$13.8K	0.01%	659
2019 Q4	$227K	Buy	+2,696	New	+$218K	0.02%	695

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Banque Cantonale Vaudoise's NVCR Position: Q3 2023 in Review

Banque Cantonale Vaudoise sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 2,500 shares — an estimated $104K sold.

Banque Cantonale Vaudoise first reported a position in NVCR in Q4 2019 and held it in 15 quarters. The position peaked at $1.4M in Q2 2021. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Banque Cantonale Vaudoise reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Banque Cantonale Vaudoise sold 2,500 NovoCure shares in Q3 2023, an estimated $104K.
Banque Cantonale Vaudoise first reported a position in NovoCure in Q4 2019 and held it in 15 quarters.
Banque Cantonale Vaudoise's NovoCure position peaked at $1.4M in Q2 2021.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2023, filed 8 Nov 2023.